[go: up one dir, main page]

MX2016013704A - Conjugado farmaco-anticuerpo igf-1r y su uso para el tratamiento contra el cancer. - Google Patents

Conjugado farmaco-anticuerpo igf-1r y su uso para el tratamiento contra el cancer.

Info

Publication number
MX2016013704A
MX2016013704A MX2016013704A MX2016013704A MX2016013704A MX 2016013704 A MX2016013704 A MX 2016013704A MX 2016013704 A MX2016013704 A MX 2016013704A MX 2016013704 A MX2016013704 A MX 2016013704A MX 2016013704 A MX2016013704 A MX 2016013704A
Authority
MX
Mexico
Prior art keywords
drug
antibody
igf
treatment
conjugate
Prior art date
Application number
MX2016013704A
Other languages
English (en)
Other versions
MX372912B (es
Inventor
Goetsch Liliane
Beau-Larvor Charlotte
Perez Michel
Rilatt Ian
Broussas Matthieu
Francois Haeuw Jean
Champion Thierry
Robert Alain
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2016013704A publication Critical patent/MX2016013704A/es
Publication of MX372912B publication Critical patent/MX372912B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con un conjugado fármaco-anticuerpo con capacidad de unión a IGF-1R. Considerando un aspecto, la invención se relaciona con un conjugado fármaco-anticuerpo que comprende un anticuerpo capaz unirse a IGF-1R, tal anticuerpo se conjuga con al menos un fármaco seleccionado a partir de derivados de dolastatina 10 y auristatinas. La invención también comprende un método de tratamiento y el uso de dicho conjugado fármaco-anticuerpo para el tratamiento contra el cáncer.
MX2016013704A 2014-04-25 2015-04-27 Conjugado farmaco-anticuerpo igf-1r y su uso para el tratamiento contra el cancer. MX372912B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305620 2014-04-25
PCT/EP2015/059045 WO2015162291A1 (en) 2014-04-25 2015-04-27 Igf-1r antibody-drug-conjugate and its use for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2016013704A true MX2016013704A (es) 2017-03-31
MX372912B MX372912B (es) 2020-04-27

Family

ID=50630736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013704A MX372912B (es) 2014-04-25 2015-04-27 Conjugado farmaco-anticuerpo igf-1r y su uso para el tratamiento contra el cancer.

Country Status (27)

Country Link
US (2) US10633448B2 (es)
EP (2) EP3134124B1 (es)
JP (1) JP6258523B2 (es)
KR (1) KR101795984B1 (es)
CN (1) CN106456800B (es)
AU (1) AU2015250759B2 (es)
BR (1) BR112016024619A2 (es)
CA (1) CA2946469C (es)
CY (1) CY1121783T1 (es)
DK (1) DK3134124T3 (es)
ES (1) ES2727103T3 (es)
HR (1) HRP20190888T8 (es)
HU (1) HUE044862T2 (es)
IL (1) IL248455B (es)
LT (1) LT3134124T (es)
MA (2) MA39909B1 (es)
MX (1) MX372912B (es)
MY (1) MY186711A (es)
PL (1) PL3134124T3 (es)
PT (1) PT3134124T (es)
RS (1) RS58742B1 (es)
RU (1) RU2692563C2 (es)
SA (1) SA516380120B1 (es)
SI (1) SI3134124T1 (es)
TN (1) TN2016000472A1 (es)
UA (1) UA120364C2 (es)
WO (1) WO2015162291A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3134124T (lt) * 2014-04-25 2019-05-27 Pierre Fabre Médicament Igf-1r antikūno ir vaisto konjugatas, ir jo panaudojimas vėžio gydymui
US10858423B2 (en) 2015-10-26 2020-12-08 Pierre Fabre Medicament Composition for the treatment of IGF-1R expressing cancer
WO2017153432A1 (en) 2016-03-07 2017-09-14 Pierre Fabre Medicament A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
EP3856258B1 (en) 2018-09-27 2024-07-31 Pierre Fabre Medicament Sulfomaleimide-based linkers and corresponding conjugates
CN111327570B (zh) 2018-12-14 2021-09-17 北京京东尚科信息技术有限公司 验证方法、装置和计算机可读存储介质
EP3735991A1 (fr) 2019-05-06 2020-11-11 Pierre Fabre Medicament Adc pour un traitement concomitant ou postérieur au docétaxel
CA3174297A1 (en) 2020-04-02 2021-10-07 Jeremy R. Duvall Antibody drug conjugates comprising sting agonists
EP3909612A1 (en) 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition of nanoparticles
CN118059229A (zh) * 2020-10-14 2024-05-24 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
JP2025519600A (ja) * 2022-06-10 2025-06-26 アセリリン， インコーポレイテッド 抗ｉｇｆ－１ｒ抗体組成物
EP4353220A1 (en) 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate
WO2024180233A1 (en) 2023-03-02 2024-09-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts A therapeutic hpv vaccine based on validated target epitopes
CR20250458A (es) 2023-03-30 2025-11-21 Revolution Medicines Inc Composiciones para inducir la hidrólisis de ras gtp y sus usos
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024249596A2 (en) * 2023-05-31 2024-12-05 Lirum Therapeutics, Inc. Methods for treating igf-1r-related cancers with an insulin-like growth factor 1 receptor ligand conjugated to a cytotoxic agent
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1995009864A1 (en) 1993-10-01 1995-04-13 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivative
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP1753463A2 (en) * 2004-06-01 2007-02-21 Genentech, Inc. Antibody drug conjugates and methods
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
EP1940470B1 (en) 2005-09-26 2013-04-17 Medarex, Inc. Antibody-drug conjugates and their use
WO2008079849A2 (en) 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
PE20090190A1 (es) 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
AR066476A1 (es) 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
MY188455A (en) 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
RU2556129C2 (ru) 2008-04-11 2015-07-10 Сиэтл Дженетикс, Инк. Диагностика и лечение злокачественных опухолей поджелудочной железы, яичников и других злокачественных опухолей
CA2754531A1 (en) 2009-03-06 2010-09-30 Seattle Genetics, Inc. Antibody drug conjugates (adc) that bind to 24p4c12 proteins
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
CA2801971C (en) 2010-06-10 2018-07-24 Hans-Georg Lerchen Novel auristatin derivatives and their use
JP5933562B2 (ja) 2010-09-29 2016-06-15 シアトル ジェネティックス， インコーポレイテッド Ｎ−カルボキシアルキル−アウリスタチンおよびその使用
ES2730941T7 (es) * 2010-10-22 2020-05-27 Seattle Genetics Inc Efectos sinérgicos entre los conjugados de conjugados anticuerpo-fármaco a base de auristatina e inhibidores de la ruta PI3K-AKT-mTOR
EP2635310A2 (en) 2010-11-05 2013-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US9029406B2 (en) 2011-03-16 2015-05-12 Seattle Genetics, Inc N-carboxyalkylauristatins and use thereof
WO2012142164A1 (en) * 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
EP3470413A3 (en) 2011-05-27 2019-08-07 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
MX371526B (es) 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2874854C (en) 2012-06-07 2023-03-14 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
CN111499684B (zh) 2012-06-19 2024-10-22 Ambrx公司 抗cd70抗体药物结合物
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
AU2013302273A1 (en) 2012-08-14 2015-02-19 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
EP2934596A1 (en) 2012-12-21 2015-10-28 Glykos Finland Oy Linker-payload molecule conjugates
FR3005051A1 (fr) 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
PT3134125T (pt) 2014-04-25 2020-01-13 Pf Medicament Conjugado-fármaco-anticorpo e sua utilização para o tratamento de cancro
LT3134124T (lt) * 2014-04-25 2019-05-27 Pierre Fabre Médicament Igf-1r antikūno ir vaisto konjugatas, ir jo panaudojimas vėžio gydymui
KR102357032B1 (ko) * 2014-04-25 2022-02-08 피에르 파브르 메디카먼트 Igf-1r 항체 및 암 치료를 위한 운반체를 어드레싱하는 그의 용도
US10858423B2 (en) * 2015-10-26 2020-12-08 Pierre Fabre Medicament Composition for the treatment of IGF-1R expressing cancer

Also Published As

Publication number Publication date
PL3134124T3 (pl) 2019-09-30
CA2946469C (en) 2019-10-29
IL248455A0 (en) 2016-11-30
MA47811A (fr) 2019-06-19
DK3134124T3 (da) 2019-05-06
TN2016000472A1 (en) 2018-04-04
JP6258523B2 (ja) 2018-01-10
CA2946469A1 (en) 2015-10-29
CN106456800B (zh) 2018-05-01
KR20160146817A (ko) 2016-12-21
HUE044862T2 (hu) 2019-11-28
UA120364C2 (uk) 2019-11-25
BR112016024619A2 (pt) 2017-10-10
WO2015162291A1 (en) 2015-10-29
IL248455B (en) 2020-01-30
MX372912B (es) 2020-04-27
HRP20190888T1 (hr) 2019-07-12
CN106456800A (zh) 2017-02-22
LT3134124T (lt) 2019-05-27
ES2727103T3 (es) 2019-10-14
PT3134124T (pt) 2019-06-03
RS58742B1 (sr) 2019-06-28
HRP20190888T8 (hr) 2019-10-04
CY1121783T1 (el) 2020-07-31
MA39909B1 (fr) 2019-05-31
MA39909A (fr) 2017-03-01
RU2016145444A3 (es) 2018-11-22
EP3134124B1 (en) 2019-02-20
US20200270352A1 (en) 2020-08-27
AU2015250759B2 (en) 2017-11-30
RU2016145444A (ru) 2018-05-28
MY186711A (en) 2021-08-12
JP2017513900A (ja) 2017-06-01
SA516380120B1 (ar) 2019-02-27
US10633448B2 (en) 2020-04-28
ES2727103T8 (es) 2020-03-02
EP3134124A1 (en) 2017-03-01
US11661457B2 (en) 2023-05-30
SI3134124T1 (sl) 2019-06-28
US20170043031A1 (en) 2017-02-16
KR101795984B1 (ko) 2017-11-10
RU2692563C2 (ru) 2019-06-25
EP3498301A1 (en) 2019-06-19
AU2015250759A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
MX2016013704A (es) Conjugado farmaco-anticuerpo igf-1r y su uso para el tratamiento contra el cancer.
MX2016013999A (es) Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
BR112018006016A2 (pt) intermediário de ligante-droga, compostos conjugados de anticorpo-droga, composições farmacêuticas, métodos para tratar câncer, método de produção de um composto conjugado e conjugado de anticorpo-droga
BR112017019300A2 (pt) conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo
CY1121949T1 (el) Φαρμακοτεχνικες μορφες συζευγματος anti-egfr αντισωματος-φαρμακου
EA202091161A1 (ru) Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
BR112017013661A8 (pt) Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
PH12016501411A1 (en) Bifunctional cytotoxic agents
BR112019023246A8 (pt) melhorias farmacocinéticas de quelatos bifuncionais e usos dos mesmos
BR112015027309A2 (pt) anticorpo, composição, método de tratamento e uso de um anticorpo
CL2016001743A1 (es) Conjugados de anticuerpo-fármaco (adc) de duocarmicina para su uso en el tratamiento de cáncer de endometrio.
BR112016029842A2 (pt) conjugados de anticorpo anti-cd22-fármaco e métodos de uso dos mesmos
BR112017004953A2 (pt) imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
MX2018000135A (es) Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2).
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
BR112016010051A2 (pt) ?conjugados de anticorpo-fármaco anti-efna4?
WO2019089594A8 (en) Combination treatment with antibody-drug conjugates and cytarabine

Legal Events

Date Code Title Description
FG Grant or registration